HC Wainwright Has Negative Outlook for MIRM FY2026 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities research analysts at HC Wainwright cut their FY2026 earnings estimates for Mirum Pharmaceuticals in a note issued to investors on Thursday, May 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($3.78) per share for the year, down from their prior forecast of ($0.80). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($8.25) per share.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The firm had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm’s revenue was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.30) EPS.

Several other analysts also recently weighed in on MIRM. Royal Bank Of Canada boosted their price objective on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday. Raymond James Financial restated a “strong-buy” rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday. Citizens Jmp restated a “market outperform” rating and set a $132.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 21st. Evercore restated an “outperform” rating and set a $138.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday. Finally, Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $136.42.

Mirum Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:MIRM opened at $106.17 on Tuesday. The company has a market capitalization of $6.47 billion, a PE ratio of -7.80 and a beta of 0.52. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a twelve month low of $42.89 and a twelve month high of $112.00. The firm has a 50 day simple moving average of $94.04 and a 200-day simple moving average of $86.57.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $3,769,800.30. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $17,872,541.82. The trade was a 17.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Joanne Quan sold 7,287 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the transaction, the insider directly owned 18,864 shares in the company, valued at $1,735,110.72. The trade was a 27.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 76,806 shares of company stock worth $7,064,616. Corporate insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. increased its holdings in shares of Mirum Pharmaceuticals by 121.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,356 shares of the company’s stock valued at $125,000 after acquiring an additional 744 shares during the period. Financiere des Professionnels Fonds d investissement inc. acquired a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at $619,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at $232,000. Bank of New York Mellon Corp increased its holdings in shares of Mirum Pharmaceuticals by 3.3% in the 1st quarter. Bank of New York Mellon Corp now owns 584,523 shares of the company’s stock valued at $53,998,000 after acquiring an additional 18,944 shares during the period. Finally, Hillsdale Investment Management Inc. increased its holdings in shares of Mirum Pharmaceuticals by 25.4% in the 1st quarter. Hillsdale Investment Management Inc. now owns 59,730 shares of the company’s stock valued at $5,518,000 after acquiring an additional 12,100 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.